Meta-analysis shows significant reductions in composite kidney outcome, kidney failure, MACE, all-cause death<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
FRIDAY, Dec. 6, 2024 (HealthDay News) — Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce the risk for clinically important kidney and cardiovascular disease outcomes in individuals with type 2 diabetes, according to research published online Nov. 25 in The Lancet Diabetes & Endocrinology<\/em>.<\/p>\n Sunil V. Badve, Ph.D., from the University of New South Wales in Sydney, and colleagues conducted a meta-analysis of randomized controlled trials that compared a GLP-1 RA to placebo among participants with type 2 diabetes. Post hoc, the SELECT trial, which enrolled participants with cardiovascular disease and a body mass index of 27 kg\/m2<\/sup> or greayer without diabetes, was included. The meta-analysis included 11 trials with 85,373 participants (67,769 with type 2 diabetes).<\/p>\n The researchers found that GLP-1 RAs reduced the composite kidney outcome, kidney failure, major adverse cardiovascular events (MACE), and all-cause death compared with placebo (hazard ratios, 0.82, 0.84, 0.87, and 0.88, respectively) in participants with type 2 diabetes. On inclusion of the SELECT trial, the effect on the composite kidney outcome, kidney failure, MACE, and all-cause death was similar (hazard ratios, 0.81, 0.84, 0.86, and 0.87, respectively), with no evidence of heterogeneity between the trials. The GLP-1 RA and placebo groups had no differences in the risk for serious adverse events, including acute pancreatitis and severe hypoglycemia.<\/p>\n “Taken together, these results and the breadth of the benefits observed support an important role for GLP-1 receptor agonists as kidney-protective and heart-protective medications that could play an important role in addressing the global burden of noncommunicable diseases,” the authors write.<\/p>\n Several authors disclosed ties to the pharmaceutical industry.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n